Oxidative stress and the use of antioxidants in diabetes: Linking basic science to clinical pratice

Cardiovascular Diabetology

Volumn 4, Issue , 2005, Pages

  Johansen, Jeanette Schultz ^a   Harris, Alex K ^b   Rychly, David J ^b   Ergul, Adviye ^b,c  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY OF GEORGIA   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Antioxidants; Diabetes; Oxidative Stress

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CHROMIUM PICOLINATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIOGLITAZONE; PLACEBO; PROPIONYLCARNITINE; RAMIPRIL; RETINOL; ROSIGLITAZONE; RUBOXISTAURIN; THIOCTIC ACID; TROGLITAZONE; FREE RADICAL; REACTIVE OXYGEN METABOLITE;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; ENDOTHELIUM LESION; EXPERIMENTAL MODEL; FOLLOW UP; HUMAN; HYPERGLYCEMIA; IN VIVO STUDY; LONG TERM CARE; META ANALYSIS; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PRIMARY PREVENTION; RANDOMIZATION; REVIEW; SYSTEMATIC REVIEW; VASODILATATION; ANIMAL; CLINICAL TRIAL (TOPIC); EXPERIMENTAL DIABETES MELLITUS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RISK REDUCTION; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FREE RADICALS; HUMANS; HYPERGLYCEMIA; OXIDATIVE STRESS; PRACTICE GUIDELINES AS TOPIC; REACTIVE OXYGEN SPECIES; RISK REDUCTION BEHAVIOR;

EID: 26844564082     PISSN: 14752840     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-4-5     Document Type: Review

References (79)

1. Pyorala K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987, 3(2):463-524.
2. Laakso M: Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999, 48(5):937-942.
3. American Diabetes Association: National diabetes fact sheet. 2002 [http://www.diabetes.org/diabetes-statistics.jsp].
4. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329(14):977-986.
5. Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care 1996, 19(3):257-267.
6. Ceriello A: New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 2003, 26(5):1589-1596.
7. Ceriello A, Motz E: Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004, 24(5):816-823.
8. Turko IV, Marcondes S, Murad F: Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoA-transferase. Am J Physiol Heart Circ Physiol 2001, 281(6):H2289-2294.
9. Maritim AC, Sanders RA, Watkins JB 3rd: Diabetes, oxidative stress, and antioxidants: A review. J Biochem Mol Toxicol 2003, 17(1):24-38.
10. Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002, 23(5):599-622.
11. Vega-Lopez S, Devaraj S, Jialal I: Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular disease. J Investig Med 2004, 52(1):24-32.
12. Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Are oxidative stress-activated signaling pathways mediators of insulin resistance and {beta}-cell dysfunction? Diabetes 2003, 52(1):1-8.
13. Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury: Part I: Basic mechanisms and in vivo monitoring of ROS. Circulation 2003, 108(16):1912-1916.
14. Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 2003, 108(17):2034-2040.
15. Taniyama Y, Griendling KK: Reactive oxygen species in the vasculature: Molecular and cellular mechanisms. Hypertension 2003, 42(6):1075-1081.
16. Boullier A, Bird DA, Chang MK, Dennis EA, Friedman P, Gillotre-Taylor K, Horkko S, Palinski W, Quehenberger O, Shaw P, et al.: Scavenger receptors, oxidized LDL, and atherosclerosis. Ann N Y Acad Sci 2001, 947:214-222.
17. Liu Y, Gutterman DD: The coronary circulation in diabetes: influence of reactive oxygen species on K+ channel-mediated vasodilation. Vascul Pharmacol 2002, 38(1):43-49.
18. Liu Y, Terata K, Chai Q, Li H, Kleinman LH, Gutterman DD: Peroxynitrite inhibits Ca2+-activated K+ channel activity in smooth muscle of human coronary arterioles. Circ Res 2002, 91(11):1070-1076.
19. Soriano FG, Virag L, Szabo C: Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J Mol Med 2001, 79(8):437-448.
20. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004, 65(3):1009-1016.
21. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM: Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 2000, 86(9):E85-90.
22. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM: Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002, 105(14):1656-1662.
23. Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L, Taboga C: Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001, 44(7):834-838.
24. Aliciguzel Y, Ozen I, Aslan M, Karayalcin U: Activities of xanthine oxidoreductase and antioxidant enzymes in different tissues of diabetic rats. J Lab Clin Med 2003, 142(3):172-177.
25. Kitada M, Koya D, Sugimoto T, Isono M, Araki S, Kashiwagi A, Haneda M: Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 2003, 52(10):2603-2614.
26. Etoh T, Inoguchi T, Kakimoto M, Sonoda N, Kobayashi K, Kuroda J, Sumimoto H, Nawata H: Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabetologia 2003, 46(10):1428-1437.
27. Ergul A, Schultz Johansen J, Stromhaug C, Harris AK, Hutchinson J, Tawfik A, Rahimi A, Rhim E, Wells B, Caldwell RW, et al.: Vascular dysfunction of venous bypass conduits is mediated by reactive oxygen species in diabetes: Role of endothelin-1. J Pharmacol Exp Ther 2004, 313:70-77.
28. Amiri F, Shaw S, Wang X, Tang J, Waller JL, Eaton DC, Marrero MB: Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int 2002, 61(5):1605-1616.
29. Green K, Brand MD, Murphy MP: Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 2004, 53(Suppl 1):S110-118.
30. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, et al.: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404(6779):787-790.
31. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414(6865):813-820.
32. Kaul N, Siveski-Iliskovic N, Hill M, Khaper N, Seneviratne C, Singal PK: Probucol treatment reverses antioxidant and functional deficit in diabetic cardiomyopathy. Mol Cell Biochem 1996, 160-161:283-288.
33. Hayden MR, Tyagi SC: Myocardial redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and congestive heart failure. Med Sci Monit 2003, 9(7):SR35-52.
34. Linke A, Adams V, Schulze PC, Erbs S, Gielen S, Fiehn E, Mobius-Winkler S, Schubert A, Schuler G, Hambrecht R: Antioxidative effects of exercise training in patients with chronic heart failure: increase in radical scavenger enzyme activity in skeletal muscle. Circulation 2005, 111(14):1763-1770.
35. Cristina Polidori M, Pratico D, Savino K, Rokach J, Stahl W, Mecocci P: Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. J Card Fail 2004, 10(4):334-338.
36. Hensley K, Robinson KA, Gabbita SP, Salsman S, Floyd RA: Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med 2000, 28(10):1456-1462.
37. Hensley K, Benaksas EJ, Bolli R, Comp P, Grammas P, Hamdheydari L, Mou S, Pye QN, Stoddard MF, Wallis G, et al.: New perspectives on vitamin E: gamma-tocopherol and carboxyelthylhydroxychroman metabolites in biology and medicine. Free Radic Biol Med 2004, 36(1):1-15.
38. Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD: Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002, 56(11):1137-1142.
39. Hodgson JM, Watts GF: Can coenzyme Q10 improve vascular function and blood pressure? Potential for effective therapeutic reduction in vascular oxidative stress. Biofactors 2003, 18(1-4):129-136.
40. Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, Burke V: Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia 2002, 45(3):420-426.
41. Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner ER: L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 2001, 276(1):40-47.
42. Mekinova D, Chorvathova V, Volkovova K, Staruchova M, Grancicova E, Klvanoca J, Ondreicka R: Effect of intake of exogenous vitamins C, E and beta-carotene on the antioxidative status in kidneys of rats with streptozotocin-induced diabetes. Nahrung 1995, 39(4):257-261.
43. Kedziora-kornatowska K, Szram S, Kornatowski T, Szadujkis-Szadurski L, Kedziora J, Bartosz G: Effect of vitamin E and vitamin C supplementation of antioxidative state and renal glomerular basement membrane thickness in diabetic kidney. Exp Nephrology 2003, 95:134-143.
44. Cinar M, Ulker S, Alper G, Evinc A: Effect of dietary vitamin E supplementation on vascular reactivity of thoracic aorta in streptozotocin-diabetic rats. Pharmacology 2001, 62(1):56-64.
45. Obrosova I, Fathallah L, Greene D: Early changes in lipid peroxidation and antioxidative defense in rat retina. Eur J Pharm 2000, 398:139-146.
46. Kocak G, Aktan F, Canbolat O, Ozogul C, Elberg S, Yildizoglu-Ari N, Karasu C: Alpha-lipoic acid treatment ameliorates metabolic parameters, blood pressure, vascular reavtivity and morphology of vessels already damaged by streptozotocin-diabetes. Diab Nutr Metab 2000, 13:308-318.
47. Rauscher F, Sanders R, Watkins JI: Effects of coenzyme Q10 treatment on antioxidant pathways in normal and streptozotocin-induced diabetic rats. J Biochem Mol Toxicol 2001, 15:41-46.
48. Maritim A, Sanders R, Watkins JI: Effects of alpha-lipoic acid on biomarkers of oxidative stress in streptozotic-induced diabetic rats. J Nutr Biochem 2003, 14(5):288-294.
49. Brands MW, Bell TD, Gibson B: Nitric oxide may prevent hypertension early in diabetes by counteracting renal actions of superoxide. Hypertension 2004, 43(1):57-63.
50. Skyrme-Jones RA, O'Brien RC, Berry KL, Meredith IT: Vitamin E supplementation improves endothelial function in type I diabetes mellitus: a randomized, placebo-controlled study. J Am Coll Cardiol 2000, 36(1):94-102.
51. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Keaney JF Jr, Creager MA: Oral antioxidant therapy improves endothelial function in Type 1 but not Type 2 diabetes mellitus. Am J Physiol 2003, 285(6):H2392-2398.
52. Gaede P, Poulsen HE, Parving HH, Pedersen O: Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients. Diabet Med 2001, 18(9):756-760.
53. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342(3):154-160.
54. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, et al.: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000, 356(9237):1213-1218.
55. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N Engl J Med 2003, 348(5):383-393.
56. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A: Primary prevention of cardiovascular events with low-dose aspirin and Vitamin E in Type 2 diabetic patients: Results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003, 26(12):3264-3272.
57. Lonn EM, Yusuf S, Dzavik V, Doris CI, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley WA, Teo KK: Effects of ramipril and vitamin E on atherosclerosis: The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001, 103(7):919-925.
58. Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, Mann JFE, Gerstein HC: Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: Results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 2002, 25(11):1919-1927.
59. Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schutte K, Gries FA: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995, 38(12):1425-1433.
60. Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Moller W, Tritschler HJ, Mehnert H: Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 1999, 31(3):171-179.
61. Ziegler D, Hanefeld M, Ruhnau K, Hasche H, Lobisch M, Schutte K, Kerum G, Malessa R: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999, 22(8):1296-1301.
62. Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G: Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care 1997, 20(3):369-373.
63. Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O'Brien PC, et al.: The sensory symptoms of diabetic polyneuropathy are improved with {alpha}-Lipoic Acid: The SYDNEY Trial. Diabetes Care 2003, 26(3):770-776.
64. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004, 21(2):114-121.
65. Dobrian AD, Davies MJ, Schriver SD, Lauterio TJ, Prewitt RL: Oxidative stress in a rat model of obesity-induced hypertension. Hypertension 2001, 37(2 Part 2):554-560.
66. Bagi Z, Koller A, Kaley G: PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am J Physiol 2004, 286(2):H742-748.
67. Fukui T, Noma T, Mizushige K, Aki Y, Kimura S, Abe Y: Dietary troglitazone decreases oxidative stress in early stage type II diabetic rats. Life Sci 2000, 66(21):2043-2049.
68. Iida KT, Kawakami Y, Suzuki M, Shimano H, Toyoshima H, Sone H, Shimada K, Iwama Y, Watanabe Y, Mokuno H, et al.: Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. Am J Physiol 2003, 284(6):E1125-1130.
69. Wilson SH, Simari RD, Best PJ, Peterson TE, Lerman LO, Aviram M, Nath KA, Holmes DR Jr, Lerman A: Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2001, 21(1):122-128.
70. Takayama T, Wada A, Tsutamoto T, Ohnishi M, Fujii M, Isono T, Horie M: Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor. Circ J 2004, 68(11):1067-1075.
71. Haendeler J, Hoffmann J, Zeiher AM, Dimmeler S: Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation 2004, 110(7):856-861.
72. Deakin S, Leviev I, Guernier S, James RW: Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol 2003, 23(11):2083-2089.
73. Touyz RM: Reactive oxygen species and angiotensin II signaling in vascular cells - implications in cardiovascular disease. Braz J Med Biol Res 2004, 37(8):1263-1273.
74. Touyz RM, Schiffrin EL: Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells. Hypertension 1999, 34(4 Pt 2):976-982.
75. Berry C, Anderson N, Kirk AJ, Dominiczak AF, McMurray JJ: Renin angiotensin system inhibition is associated with reduced free radical concentrations in arteries of patients with coronary heart disease. Heart 2001, 86(2):217-220.
76. Steinberg D, Witztum JL: Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 2002, 105(17):2107-2111.
77. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D: Antioxidant therapy: A new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 2001, 53(1):135-159.
78. Szabo C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L, Soriano FG, Van Duzer JH, Williams W, Salzman AL, et al.: Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med 2002, 8(10):571-580.
79. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witztum JL: Antioxidant vitamin supplements and cardiovascular disease. Circulation 2004, 110(5):637-641